Latest News - Ophthotech

Tuesday, September 19, 2017 | Clinical Trials, Retina, Ophthotech

Ophthotech Provides Update on Zimura Complement Programs for Treatment of Eye Diseases

Ophthotech announced the initiation of an open-label phase 2a clinical trial of Zimura (avacincaptad pegol), the company’s complement factor C5 inhibitor, in patients with wet age-related macula…

Read the full story

Monday, August 14, 2017 | Clinical Trials, Retina, AMD, Ophthotech

Ophthotech's Fovista Fails Third Phase 3 Trial in Wet AMD

Ophthotech announced that the prespecified primary endpoint of mean change in visual acuity at 12 months was not achieved in its phase 3 clinical trial investigating the superiority of Fovis…

Read the full story

Wednesday, July 26, 2017 | Clinical Trials, Earnings & Financials, AMD, Ophthotech

Ophthotech Expands Focus with Development for Ophthalmic Orphan Diseases

Ophthotech announced that the company is pursuing a strategy to leverage its clinical experience and retina expertise to identify and develop therapies to treat multiple orphan ophthalmic diseases for…

Read the full story

Wednesday, April 26, 2017 | Management/Leadership, Ophthotech

Ophthotech Announces Leadership Transition Effective July 1, 2017

Ophthotech announced that David R. Guyer, MD, a cofounder, Chief Executive Officer and Chairman of the Board of Ophthotech, will transition to Executive Chairman effective July 1, 2017. Concurrent wit…

Read the full story

Wednesday, February 01, 2017 | Management/Leadership, AMD, Ophthotech

Ophthotech Announces Strategic Review Plan

Ophthotech announced that it has initiated a plan to review its strategic alternatives in order to maximize shareholder value. Without limiting any option, the principal focus of this plan is to activ…

Read the full story

Monday, December 12, 2016 | Clinical Trials, Retina, Ophthotech

Ophthotech Fails Phase 3 Trials of Fovista in Wet Age-Related Macular Degeneration

Ophthotech announced that the prespecified primary endpoint of mean change in visual acuity at 12 months was not achieved in its two pivotal phase 3 clinical trials investigating the superio…

Read the full story

Monday, October 31, 2016 | Clinical Trials, Ophthotech

Ophthotech Announces the Publication of Fovista in Combination with Lucentis Phase 2b Study Results

Ophthotech announced that the phase 2b study results of Fovista (pegpleranib), the company's anti-PDGF agent administered in combination with Lucentis (ranibizumab) anti-VEGF therapy for the treat…

Read the full story

Monday, June 20, 2016 | Clinical Trials, Ophthotech

Ophthotech Completes Patient Recruitment in Phase 3 Trial of Fovista Anti-PDGF Therapy in Combination with Eylea or Avastin in Wet AMD

Ophthotech announced the completion of patient recruitment in its phase 3 trial of Fovista (pegpleranib) anti-PDGF therapy, in combination with Eylea (aflibercept) or Avastin (bevacizumab), for the tr…

Read the full story

Thursday, April 28, 2016 | Management/Leadership, Ophthotech

Carmen A. Puliafito, MD, MBA, Former Dean of Keck School of Medicine of the University of Southern California, Joins Ophthotech as Chief of Strategic Development

Ophthotech announced the appointment of Carmen A. Puliafito, MD, MBA, as Chief of Strategic Development, according to a company news release. As one of the world's leading experts in ophthalmol…

Read the full story

Wednesday, January 27, 2016 | Clinical Trials, Ophthotech

Ophthotech Announces First Patient Dosed in Zimura Phase 2/3 Study to Evaluate Treatment in Patients with Geographic Atrophy

Ophthotech announced that the first patient has been dosed in a phase 2/3 clinical study of Zimura (avacincaptad pegol sodium), an inhibitor of complement factor C5, in patients with geographic atroph…

Read the full story

Tuesday, January 05, 2016 | Management/Leadership, Ophthotech

Glenn P. Sblendorio to Join Ophthotech as Executive Vice President, Chief Operating Officer and Chief Financial Officer

Ophthotech Corporation announced that Glenn P. Sblendorio has agreed to join the company as executive vice president, chief operating officer, and chief financial officer on April 1, 2016, according t…

Read the full story

Wednesday, November 18, 2015 | Earnings & Financials, Retina, Genentech, Ophthotech, Roche

Genentech Elects to Exercise Its Right to Opt-in to the Novartis Portion of the Ophthotech/Novartis Ex-US Agreement for Fovista to Treat Wet AMD

Ophthotech announced that Genentech has elected to exercise its option to participate in the financial arrangements relating to Novartis’ rights under the Ophthotech/Novartis ex-US agreement for…

Read the full story

Tuesday, October 27, 2015 | Clinical Trials, Ophthotech

Ophthotech Completes Patient Recruitment of the Second Phase 3 Pivotal Trial of Fovista Anti-PDGF Therapy in Combination with Lucentis in Wet AMD

Ophthotech announced the completion of patient recruitment for its second phase 3 trial of Fovista (pegpleranib) in combination with Lucentis (ranibizumab) for the treatment of wet age-related macular…

Read the full story

Tuesday, July 21, 2015 | Management/Leadership, Ophthotech

Ophthotech Announces New Senior Leadership Appointments

Ophthotech announced the appointment of David T. Shima, PhD, as Chief Scientific Officer, effective at the end of September, according to a company news release. Dr. Shima joins Ophthotech from Roche,…

Read the full story

Tuesday, May 12, 2015 | Clinical Trials, Ophthotech

Ophthotech Completes Patient Recruitment of the First Phase 3 Pivotal Trial of Fovista Anti-PDGF Therapy in Combination with Lucentis in Wet AMD

Ophthotech Corporation announced the completion of patient recruitment of its first phase 3 trial of Fovista in combination with Lucentis (ranibizumab), according to a company news release. The compan…

Read the full story
Load More